Effective on or after April 1, 20241


Injection, avacincaptad pegol, 0.1 mg 

IZERVAY is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

HCPCS Code:1


HCPCS Descriptor:1

Injection, avacincaptad pegol, 0.1 mg

10-Digit NDC:2


11-Digit NDC:2


Package Description:2

20 mg/mL solution in a single-dose glass vial

HCPCS Billing Units:*


Sites of Care:

J2782 is available for all sites of care

*One billing unit of J2782 equals 0.1 mg of avacincaptad pegol. As a result, billing for 20 units equals a 2-mg dose of IZERVAY.

Visit IZERVAYecp.com for more information


IZERVAY™ (avacincaptad pegol intravitreal solution) is indicated for the treatment of geographic

atrophy (GA) secondary to age-related macular degeneration (AMD).




  • IZERVAY is contraindicated in patients with ocular or periocular infections and in patients with active intraocular inflammation.



  • Endophthalmitis and Retinal Detachments 
  • Intravitreal injections, including those with IZERVAY, may be associated with endophthalmitis and retinal detachments. Proper aseptic injection technique must always be used when administering IZERVAY in order to minimize the risk of endophthalmitis. Patients should be instructed to report any symptoms suggestive of endophthalmitis or retinal detachment without delay and should be managed appropriately.
  • Neovascular AMD 
  • In clinical trials, use of IZERVAY was associated with increased rates of neovascular (wet) AMD or choroidal neovascularization (7% when administered monthly and 4% in the sham group) by Month 12. Patients receiving IZERVAY should be monitored for signs of neovascular AMD.
  • Increase in Intraocular Pressure 
  • Transient increases in intraocular pressure (IOP) may occur after any intravitreal injection, including with IZERVAY. Perfusion of the optic nerve head should be monitored following the injection and managed appropriately.



  • Most common adverse reactions (incidence ≥5%) reported in patients receiving IZERVAY were conjunctival hemorrhage, increased IOP, blurred vision, and neovascular age-related macular degeneration.


Please click here for IZERVAY full Prescribing Information.


1. Centers for Medicare & Medicaid Services. CMS HCPCS Application Summaries and Coding Recommendations: Fourth Quarter, 2023HCPCS Coding Cycle. Accessed February 21, 2024. https://www.cms.gov/files/document/2023-hcpcs-application-summary-quarter-4-2023-drugs-and-biologicals-updated-02/05/2024.pdf

2. IZERVAY™ (avacincaptad pegol intravitreal solution) Prescribing Information. IVERIC bio, Inc., Parsippany, NJ 07054.

Copyright © 2024 Astellas Pharma Inc. or its affiliates. All trademarks are the property of their respective owners. US-AP-2400063 03/24